FON-2021-0568 IFG.pdf (393.63 kB)

Infographic: Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the phase 3 ICARIA-MM study

figure

posted on 2021-09-15, 08:37 authored by Paul G. Richardson, Simon J. Harrison, Sara Bringhen, Fredrik Schjesvold, Kwee Yong, Frank Campana, Solenn Le-Guennec, Sandrine Mac, Meletios A. Dimopoulos

Infographic – Summary of the Phase 3 ICARIA-MM study key subgroup analyses review

Funding

Sanofi

History

Usage metrics

Future Oncology

Keywords

anti-CD38 monoclonal antibody isatuximab multiple myeloma ICARIA-MM high-risk cytogenetics prior lines refractory relapsed renal impairment elderly patients Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0